FDA approves blinatumomab in the consolidation phase of B-cell precursor acute lymphoblastic leukemia, regardless of MRD status

Evidence stage: High-Certainty EvidenceRegulatory status: FDA-approved for the exact stated cancer/useGuideline status: Not addressed

The FDA approved blinatumomab (Blincyto) for the consolidation phase of treatment in adults and children (1 month and older) with CD19-positive, Philadelphia-chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL), regardless of measurable residual disease (MRD) status — expanding its prior approvals, which were limited to MRD-positive or relapsed/refractory disease. The approval was supported primarily by the phase 3 ECOG-ACRIN E1910 trial (ClinicalTrials.gov NCT02003222; primary publication DOI 10.1056/NEJMoa2312948), an international, randomized study of 224 adults 30-70 years old in MRD-negative remission after induction/intensification chemotherapy, randomized to consolidation chemotherapy with or without blinatumomab. The trial reported significantly longer overall survival with blinatumomab added to chemotherapy.

What This Means

In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the primary trial publication reported a 3-year overall-survival rate of 85% with blinatumomab versus 68% with chemotherapy alone (hazard ratio 0.41, 95% CI 0.23-0.73, P=.002). The FDA's own approval summary cites a closely related but not identical figure for the same analysis (hazard ratio 0.42, 95% CI 0.24-0.75, P=.003) — both figures are preserved here rather than one being silently chosen, since they likely reflect slightly different analysis cutoffs of the same underlying trial data.

What This Doesn't Mean

This record's efficacy claims are scoped to the adult, MRD-negative E1910 population specifically studied in the primary publication — the FDA approval itself is broader (covers pediatric patients and is not restricted by MRD status), supported additionally by two pediatric relapse trials (Study 20120215 and Study AALL1331) this record has not independently reviewed in detail.

Why It Matters

A randomized, phase 3, statistically significant overall-survival benefit is a high evidentiary bar in oncology, and this approval extends a previously narrower indication (MRD-positive or relapsed/refractory disease only) to a much larger population of newly diagnosed, MRD-negative patients — a meaningful expansion of who can benefit from this immunotherapy.

Promise & Proof

Proof — strength of the evidence 5 / 5
  • Base score from evidence stage: High-Certainty Evidence.
  • FDA-approved for the exact stated cancer/use.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • A distinct follow-on/confirmatory study or trial is already cited as a secondary source — the field is already building on this finding.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults 30 to 70 years old with CD19-positive, Philadelphia-chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in measurable-residual-disease-negative (MRD-negative) remission after induction and intensification chemotherapy, randomized to consolidation chemotherapy with or without blinatumomab. The FDA's broader approval also covers pediatric patients (1 month and older) and is not restricted to MRD-negative disease, supported by two additional pediatric relapse trials this record does not independently detail. (Adults)

This is specifically an FDA-approved use in the consolidation phase of treatment, not a standalone or first-line therapy, and requires CD19-positive, Philadelphia-chromosome-negative disease status. Blinatumomab carries known risks (including cytokine release syndrome and neurological toxicities) that must be disclosed as part of counseling, not minimized — this record does not itself detail the full safety profile and that should be added before publication.

Full evidence details
Study design
Randomized controlled trial
Sample size
224

Funding & Conflicts

Trial sponsor: National Cancer Institute (NCI)/ECOG-ACRIN Cancer Research Group, in collaboration with Amgen (blinatumomab's manufacturer) — not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status
FDA-approved for the exact stated cancer/use
Indication
Adults and pediatric patients 1 month and older with CD19-positive, Philadelphia-chromosome-negative B-cell precursor acute lymphoblastic leukemia, in the consolidation phase of multiphase chemotherapy, regardless of measurable residual disease status.
Biomarker requirement
CD19-positive, Philadelphia chromosome-negative
Decision date
2024-06-14
Source
Regulator record (opens in a new tab)

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-13

Primary evidence supporting this story

Additional context

Why Should I Trust This?

  • 1 source at Tier 2 — Peer-reviewed primary research, trial registries, regulatory documents, official conference abstracts
  • Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "Legacy / Unverified" to "In editorial review".
  2. Status change — Status changed from "In editorial review" to "Verified".

Last reviewed

Related discoveries

FDA approves blinatumomab in the consolidation phase of B-cell precursor acute lymphoblastic leukemia, regardless of MRD status

https://cancerdiscoveries.com/discoveries/fda-approves-blinatumomab-in-the-consolidation-phase-of-b-cell-precursor-acute-lymphoblastic-leukemia-regardless-of-mrd-status/

Evidence stage: High-Certainty Evidence

What This Means

In the randomized, phase 3 ECOG-ACRIN E1910 trial, adding blinatumomab to consolidation chemotherapy significantly extended overall survival compared with chemotherapy alone in adults with MRD-negative B-cell precursor ALL — the primary trial publication reported a 3-year overall-survival rate of 85% with blinatumomab versus 68% with chemotherapy alone (hazard ratio 0.41, 95% CI 0.23-0.73, P=.002). The FDA's own approval summary cites a closely related but not identical figure for the same analysis (hazard ratio 0.42, 95% CI 0.24-0.75, P=.003) — both figures are preserved here rather than one being silently chosen, since they likely reflect slightly different analysis cutoffs of the same underlying trial data.

What This Doesn't Mean

This record's efficacy claims are scoped to the adult, MRD-negative E1910 population specifically studied in the primary publication — the FDA approval itself is broader (covers pediatric patients and is not restricted by MRD status), supported additionally by two pediatric relapse trials (Study 20120215 and Study AALL1331) this record has not independently reviewed in detail.

Why It Matters

A randomized, phase 3, statistically significant overall-survival benefit is a high evidentiary bar in oncology, and this approval extends a previously narrower indication (MRD-positive or relapsed/refractory disease only) to a much larger population of newly diagnosed, MRD-negative patients — a meaningful expansion of who can benefit from this immunotherapy.

Primary sources

  • ECOG-ACRIN E1910 trial primary results: blinatumomab in MRD-negative B-cell precursor ALL (NEJM) — https://doi.org/10.1056/NEJMoa2312948 (DOI 10.1056/NEJMoa2312948, PMID 39047240)

Date verified: 2026-08-13

Correction status: No correction or retraction